PHILADELPHIA, Pa, July 20, 2020 — PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders, today announced the appointment of Kelly Beck as Chief Executive Officer and Board Director.

“Kelly brings extraordinary skills and experience to PolyCore”, said Jim Harris, PolyCore Therapeutics’s Chairman of the Board. “Kelly’s depth of business expertise is a perfect complement to the scientific expertise of our founding team. As we move our first program closer to the clinic, it was the right time to hire our first CEO and enhance our ability to deliver high-value therapeutics for the future.”

Ms. Beck brings over 20 years of knowledge and experience from biotechnology and clinical research organizations. She most recently served as vice president, investor relations and administration with Ocugen, Inc., where she played an instrumental role in the growth of the company, including through its reverse merger to become a publicly traded company on the Nasdaq exchange. Prior to Ocugen, she held roles of increasing responsibility at PRA Health Sciences, DrugDev and Tengion. Ms. Beck holds a B.S. in Business Administration with a concentration in Accounting from Millersville University, a M.S. in Human Resource Development from Villanova University and a M.B.A. with a concentration in Biotechnology and Health Industry Management from Penn State University.

“I’m thrilled to join PolyCore as the company advances its preclinical studies to prepare for an IND filing in the next year,” said Beck. “There are millions of patients today suffering from Parkinson’s Disease, many of whom are affected by the development of debilitating dyskinesia. I look forward to advancing new and innovative therapies that will improve these patients’ quality of life.”

About PolyCore Therapeutics

PolyCore Therapeutics LLC is a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders. PolyCore is currently in preclinical studies for its lead compound, PCT-3012, a novel small molecule for treatment of Parkinson’s motor symptoms in patients with early- to mid-stag e Parkinson’s Disease. For more information, visit http://www.polycoretherapeutics.com.